These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20075406)

  • 1. Osteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates.
    Ryan P; Saleh I; Stassen LF
    Postgrad Med J; 2009 Dec; 85(1010):674-7. PubMed ID: 20075406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
    Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
    Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw: who gets it, and why?
    Reid IR
    Bone; 2009 Jan; 44(1):4-10. PubMed ID: 18948230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient.
    Koka S; Clarke BL; Amin S; Gertz M; Ruggiero SL
    Int J Prosthodont; 2007; 20(2):115-22. PubMed ID: 17455429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of bisphosphonate-induced osteonecrosis of the jaw.
    Schilling J
    Northwest Dent; 2008; 87(3):34-5, 37-8, 40. PubMed ID: 18663869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
    Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy.
    Erkan M; Bilgi O; Mutluoğlu M; Uzun G
    JOP; 2009 Sep; 10(5):579-80; author reply 581-2. PubMed ID: 19734644
    [No Abstract]   [Full Text] [Related]  

  • 11. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
    Fehm T; Felsenberg D; Krimmel M; Solomayer E; Wallwiener D; Hadjii P
    Breast; 2009 Aug; 18(4):213-7. PubMed ID: 19651512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jaw due to bisphosphonates.
    Prescrire Int; 2008 Oct; 17(97):202-3. PubMed ID: 19536938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw and bisphosphonates--putting the risk in perspective.
    Bolland M; Hay D; Grey A; Reid I; Cundy T
    N Z Med J; 2006 Dec; 119(1246):U2339. PubMed ID: 17151713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses.
    Morris M; Cruickshank S
    Eur J Oncol Nurs; 2010 Jul; 14(3):205-10. PubMed ID: 20129822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
    Diel IJ; Fogelman I; Al-Nawas B; Hoffmeister B; Migliorati C; Gligorov J; Väänänen K; Pylkkänen L; Pecherstorfer M; Aapro MS
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):198-207. PubMed ID: 17855108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bisphosphonate-related osteonecrosis of the jaw].
    Franken AA; van Blijderveen NJ; Witjes MJ; Netelenbos CJ
    Ned Tijdschr Geneeskd; 2011; 155():A3077. PubMed ID: 21486510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management.
    Ruggiero SL; Mehrotra B
    Annu Rev Med; 2009; 60():85-96. PubMed ID: 18928335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of complications of bisphosphonates in oncology patients: jaw osteonecrosis].
    Madrid C; Jaques B; Bouferrache K; Broome M
    Rev Med Suisse; 2007 May; 3(112):1322, 1324-6, 1329-31. PubMed ID: 17596069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis.
    Jeffcoat M; Watts NB
    Gen Dent; 2008; 56(1):96-102; quiz 103-4, 111-2. PubMed ID: 18254568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.